Insight Molecular Diagnostics highlights new real-world GraftAssure data at EFI2026

• Insight Molecular Diagnostics flagged new independent real-world head-to-head findings supporting its GraftAssure transplant assay.
• Results were already presented at 39th European Immunogenetics and Histocompatibility Conference (EFI2026) on April 21-24, 2026.
• Additional clinical evidence is scheduled for presentation at 63rd European Renal Association Congress on June 3-6, 2026, followed by American Transplant Congress on June 20-24, 2026.
• Data are positioned to strengthen clinical adoption case for localized testing model, supporting push into roughly $2 billion market for kitted transplant rejection testing.
• Regulatory strategy advanced with March 25, 2026 FDA submission for GraftAssureDx, described as first kitted dd-cfDNA assay sent for review via Class II de novo pathway.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insight Molecular Diagnostics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604140800PRIMZONEFULLFEED9689147) on April 14, 2026, and is solely responsible for the information contained therein.